CYCC Cyclacel Pharmaceuticals, Inc.: Earnings per share for the last 12 months

Cyclacel Pharmaceuticals Inc. (CYCC) - corporate logo

Intellectual patents for transcription inhibitors create a formidable barrier for competitors, although early development stages remain risky. The 12-month YoY EPS trend captures this dynamics, where -8.20 expresses the latest metric level. Cyclacel Pharmaceuticals (CYCC) relies on the diversification of targeted drugs for various tumors for business resilience, yet the fierce competition for capital and the risk of clinical trial failure pose serious threats.

Cyclacel Pharmaceuticals Inc. (CYCC) Earnings per share for the last twelve months: for the period 02/11/2024 - 02/20/2024

CYCC (Cyclacel Pharmaceuticals, Inc.): analytical breakdowns and indicator data

Fundamental company valuation:CYCC Cyclacel Pharmaceuticals Inc.
Flagship merchandise of Cyclacel

Year-over-year (YoY) EPS growth (TTM) measures the change in net income per share over the last twelve months relative to the previous year. This metric reflects asset monetization efficiency and the rate of change in profitability. For Cyclacel Pharmaceuticals (CYCC), this figure depends on grant volumes and partner payments for the development of oncology drugs. By analyzing the history of EPS YoY (TTM) percentage changes, an investor assesses the stability of R&D funding. The long-term trend determines the viability of the business model.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months Inhibrx Corp (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months coherus.com|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology, Inc. CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla BCAB|Net earnings per share for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Earnings per share for the trailing year|Cellectar Biosciences - Net earnings per share for the last 12 months|Earnings per share for the last four quarters BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year APRE (aprea.com)|KZIA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Silexion (SLXN)|Earnings per share for the last twelve months nucana.com|CMRX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months